The combination of two hepatoprotective drugs was the common regimen and the duration of medication varied from 1 week to 3 months. Liver function was re-examined every 1 or 2 weeks until liver function became normal. In 32 patients (32/40, 80%), liver function recovered, whereas 8 (8/40, 20%) still presented grade 1 hepatotoxicity at the end of follow-up (Fig. 1). Four patients discontinued gefitinib therapy because of hepatotoxicity: one in the mild hepatotoxicity group and three in the severe hepatotoxicity group. Discontinuation of concurrent medications was observed in 15 patients.
Over 1000 drugs have been reported capable of inducing acute or chronic liver injury 15. The results of our study suggested that hepatotoxicity was a common adverse event during the long-term oral administration of gefitinib. The majority showed an increase in aminotransferase (28.7%), mostly a mild increase (24.7%), followed by an increase in bilirubin (9.9%) and an increase in ALP (3.0%).
There are no conflicts of interest.
1. D’Addario G, Felip E. ESMO Guidelines Working Group. Non-small-cell lung cancer
: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20:68–70.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59:225–249.
3. Ozkaya S, Findik S, Dirican A, Atici AG. Long-term survival rates of patients with stage III and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med 2012; 4:1035–1038.
4. Sánchez de Cos Escuín J, Disdier Vicente C, Corral Peñafiel J, Riesco Miranda JA, Sojo González MA, Masa Jiménez JF. Overall long-term survival in lung cancer analyzed in 610 unselected patients. Arch Bronconeumol 2004; 40:268–274.
5. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999; 86:1867–1876.
6. Wang T, Nelson RA, Bogardus A, Grannis FW Jr. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 2010; 116:1518–1525.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al.. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer
. N Engl J Med 2004; 350:2129–2139.
8. Jänne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, et al.. Outcomes of patients with advanced non-small-cell lung cancer
treated with gefitinib
(ZD 1893, ‘Iressa’) on an expanded access study. Lung Cancer 2004; 44:221–230.
9. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al.. Gefitinib
or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med 2010; 362:2380–2388.
10. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al.. Gefitinib
versus cisplatin plus docetaxel in patients with non-small-cell lung cancer
harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121–128.
11. Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, et al.. Combined survival analysis of prospective clinical trials of gefitinib
for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009; 15:4493–4498.
12. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al.. Gefitinib
or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947–957.
13. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al.. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12:735–742.
14. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al.. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol 2013; 13:239–246.
15. Juurlink DN. Drug-induced hepatotoxicity
. N Engl J Med 2003; 349:1974–1976.
16. Ho C, Davis J, Anderson F, Bebb G, Murray N. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib
. J Clin Oncol 2005; 23:8531–8533.
17. Nishino K, Imamura F, Morita S, Mori M, Komuta K, Kijima T, et al.. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib
treatment. Lung Cancer 2013; 82:299–304.
18. McKillop D, McCormick AD, Millar A, Miles GS, Phillips PJ, Hutchison M. Cytochrome P450-dependent metabolism of gefitinib
. Xenobiotica 2005; 35:39–50.
19. Takimoto T, Kijima T, Otani Y, Nonen S, Namba Y, Mori M, et al.. Polymorphisms of CYP2D6 gene and gefitinib
. Clin Lung Cancer 2013; 14:502–507.
20. Swaisland HC, Cantarini MV, Fuhr R, Holt A. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib
pharmacokinetics. Clin Pharmacokinet 2006; 45:633–644.
21. Chhun S, Verstuyft C, Rizzo-Padoin N, Simoneau G, Becquemont L, Peretti I, et al.. Gefitinib
-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol 2009; 68:226–237.
22. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al.. Multi-institutional randomized phase II trial of gefitinib
for previously treated patients with advanced non-small-cell lung cancer
(The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21:2237–2246.
23. Bliven EE, Podewils LJ. The role of chronic hepatitis in isoniazid hepatotoxicity
during treatment for latent tuberculosis infection. Int J Tuberc Lung Dis 2009; 13:1054–1060.
24. Zhang T, Jia JD. Causative agents and clinical features of 107 patients with drug-induced liver disease. Chin Hepatol 2005; 10:174–176.
25. Lu WT, Li J, Ou N, Chen N, Liu Y, Guo XJ, et al.. An analysis of 276 cases of drug-induced liver damage. Zhonghua Gan Zang Bing Za Zhi 2006; 14:832–834.
26. Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Jpn J Clin Oncol 2012; 42:528–533.
27. Kijima T, Shimizu T, Nonen S, Furukawa M, Otani Y, Minami T, et al.. Safe and successful treatment with erlotinib after gefitinib
: difference in metabolism as a possible mechanism. J Clin Oncol 2011; 29:e588–e590.
28. Kunimasa K, Yoshioka H, Iwasaku M, Nishiyama A, Korogi Y, Masuda G, et al.. Successful treatment of non-small cell lung cancer with gefitinib
after severe erlotinib-related hepatotoxicity
. Intern Med 2012; 51:431–434.
29. Seki N, Uematsu K, Shibakuki R, Eguchi K. Promising new treatment schedule for gefitinib
responders after severe hepatotoxicity
with daily administration. J Clin Oncol 2006; 24:3213–3214.